Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy (in Russian only)

Egorov E.A.; Erichev V.P.; Strahov V.V.; Petrov S.Iu.; Romanova T.B.; Vasina M.V.; Zinina V.S.; Makarova А.S.; Kazanova S.Yu.; Yartsev A.V.

doi:https://doi.org/10.17116/oftalma201913503120

Egorov E.A.

RNIMU im. N.I. Pirogova

SPIN RSCI: 9704-9451
Scopus AuthorID: 7103143758
ORCID: 0000-0002-1132-8031

Erichev V.P.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Strahov V.V.

Kafedra oftal'mologii Jaroslavskogo gosudarstvennogo meditsinskogo universiteta, ul. Revoljutsionnaja, 5, Jaroslavl', Rossijskaja Federatsija, 150000

SPIN RSCI: 7887-2560
Scopus AuthorID: 7103202082
ORCID: 0000-0003-3179-1303

Petrov S.Iu.

FGBU "NII glaznykh bolezneĭ" RAMN

Romanova T.B.

Pirogov Russian National Research Medical University, Department of Ophthalmology, 23 Veshnyakovskaya St., Moscow, Russian Federation, 111539

Vasina M.V.

Ophthalmological Center 'Doctor Visus', 14 Kalanchevskaya St., Moscow, Russian Federation, 129090

Zinina V.S.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Makarova А.S.

Research Institute of Eye Diseases, 11 A, B, Rossolimo St., Moscow, Russian Federation, 119021

Kazanova S.Yu.

Yaroslavl State Medical University, Department of Ophthalmology, 5 Revolyutsionnaya St., Yaroslavl, Russian Federation, 150000

Yartsev A.V.

Yaroslavl State Medical University, Department of Ophthalmology, 5 Revolyutsionnaya St., Yaroslavl, Russian Federation, 150000

Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy (in Russian only)

Authors:

Egorov E.A., Erichev V.P., Strahov V.V., Petrov S.Iu., Romanova T.B., Vasina M.V., Zinina V.S., Makarova А.S., Kazanova S.Yu., Yartsev A.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2019;135(3): 20‑30

DOI: 10.17116/oftalma201913503120

Read: 2723 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Egorov EA, Erichev VP, Strahov VV, et al. . Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy (in Russian only). Russian Annals of Ophthalmology. 2019;135(3):20‑30. (In Russ.)
https://doi.org/10.17116/oftalma201913503120

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Approaches for improvement of ocular surface condition in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(5):7-16

Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy. Russian Annals of Ophthalmology. 2024;(5):97-104

Perioperative prevention of bleeding in glaucoma surgery. Russian Annals of Ophthalmology. 2024;(5):118-124

Neuroprotective therapy for age-related macular degeneration. Russian Annals of Ophthalmology. 2024;(6):152-158

The results of fistulizing glaucoma surgeries in pseudophackic patients. Russian Annals of Ophthalmology. 2025;(1):45-52

Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90

Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18

Modern aspects of chronic cerebral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113

Neurocytoprotection advances in reperfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):75-88

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33

Abstract:

Purpose — to evaluate the efficacy and safety of intramuscular Retinalamin for retinoprotection in patients with open-angle glaucoma and normalized intraocular pressure (IOP). Material and methods. The study included 180 patients (355 eyes) randomized into the main (n=90) and control groups (n=90). The patients of the main group received intramuscular Retinalamin injections; the course was repeated 6 months later. Patient examination was performed at 1, 3, 6, 7, 9 and 12 months. Results. Vision acuity did not change in the main group after the treatment courses (p=0.3732, p=0.6862), nor in the control group (p=0.7751). IOP didn’t have significant changes during the whole course of the study neither in the main group (p=0.7632), nor in the control group (p=0.3921). MD index in the main group has increased from –5.52±2.76 to –4.82±2.73 dB (measurements from 6 visits: p=0.0391, p=0.0201, p=0.0302, p=0.3708, p=0.0151, p=0.0353). Control group showed negative MD trend (from –3.51±1.84 to –4.60±2.61 dB; p=0.0012). PSD index has changed from 4.63±1.60 to 4.05±1.43 dB (p=0.0081) in the main group, and from 3.73±1.19 to 4.29±1.53 dB (p=0.0027) in the control group. Average thickness of retinal nerve fiber layer (RNFL) and the volume of neuroretinal rim were stable in both the main (p=0.8039, p=0.9005) and the control groups (p=0.7448, p=0.9620). Ganglion cell complex (GCC) thickness remained stable in the main group (p=0.0377), but has decreased in the control group (p=0.0250). P50 amplitude and latency were stable in the main group (6.54±2.61—6.53±2.64 µV, p=0.0479; 48.39±3.69—50.86±4.09 ms, p=0.0271), while in the control group P50 amplitude has decreased (p=0,0031) and the latency has increased (p=0,0194). In the main group, N95 amplitude has stabilized (p=0.0141) with worsened latency (p=0.0492). N95 amplitude in the control group has worsened (p=0.0195), while latency has stabilized (p=0.3401). Conclusion. Systemic use of Retinalamin has significant retinoprotective effect confirmed by the dynamics of morphological and functional parameters in patients with POAG and IOP compensation.

Keywords:

glaucoma

neuroprotection

retinoprotection

Retinalamin

Authors:

Egorov E.A.

RNIMU im. N.I. Pirogova

SPIN RSCI: 9704-9451
Scopus AuthorID: 7103143758
ORCID: 0000-0002-1132-8031

Erichev V.P.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Strahov V.V.

Kafedra oftal'mologii Jaroslavskogo gosudarstvennogo meditsinskogo universiteta, ul. Revoljutsionnaja, 5, Jaroslavl', Rossijskaja Federatsija, 150000

SPIN RSCI: 7887-2560
Scopus AuthorID: 7103202082
ORCID: 0000-0003-3179-1303

Petrov S.Iu.

FGBU "NII glaznykh bolezneĭ" RAMN

Romanova T.B.

Pirogov Russian National Research Medical University, Department of Ophthalmology, 23 Veshnyakovskaya St., Moscow, Russian Federation, 111539

Vasina M.V.

Ophthalmological Center 'Doctor Visus', 14 Kalanchevskaya St., Moscow, Russian Federation, 129090

Zinina V.S.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Makarova А.S.

Research Institute of Eye Diseases, 11 A, B, Rossolimo St., Moscow, Russian Federation, 119021

Kazanova S.Yu.

Yaroslavl State Medical University, Department of Ophthalmology, 5 Revolyutsionnaya St., Yaroslavl, Russian Federation, 150000

Yartsev A.V.

Yaroslavl State Medical University, Department of Ophthalmology, 5 Revolyutsionnaya St., Yaroslavl, Russian Federation, 150000

Close metadata

References:

Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. The British journal of ophthalmology. 2006;90(3):262-267. https://doi.org/10.1136/bjo.2005.081224
Resnikoff S, Pascolini D, Etya’ale D, Kocur I, et al. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization. 2004;82(11):844-851.
Osborne NN, Chidlow G, Wood J, Casson R. Some current ideas on the pathogenesis and the role of neuroprotection in glaucomatous optic neuropathy. European journal of ophthalmology. 2003;13(suppl 3):19-26.
Bonomi L. Epidemiology of angle-closure glaucoma. Acta ophthalmologica Scandinavica Supplement. 2002;236:11-13.
Tielsch JM, Sommer A, Katz J, Royall RM, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. Jama. 1991;266(3):369-374.
Friedman DS, Wolfs RC, O’Colmain BJ, Klein BE, et al. Prevalence of open-angle glaucoma among adults in the United States. Archives of ophthalmology. 2004;122(4):532-538. https://doi.org/10.1001/archopht.122.4.532
Hunter DJ. Gene-environment interactions in human diseases. Nature reviews Genetics. 2005;6(4):287-298. https://doi.org/10.1038/nrg1578
Anderson DR, Drance SM, Schulzer M. Collaborative Normal-Tension Glaucoma Study G. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. American journal of ophthalmology. 2003;136(5):820-829.
Armaly MF, Krueger DE, Maunder L, Becker B, et al. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Archives of ophthalmology. 1980;98(12):2163-2171.
Heijl A, Leske MC, Bengtsson B, Hyman L, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology. 2002;120(10):1268-1279.
Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. American journal of ophthalmology. 1996;121(5):473-483.
Cockburn DM. Does reduction of intraocular pressure (IOP) prevent visual field loss in glaucoma? American journal of optometry and physiological optics. 1983;60(8):705-711.
Levin LA. Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Survey of ophthalmology. 1999;43(suppl 1):98-101.
Neacsu A, Oprean C, Curea M, Tuchila G, et al. Neuroprotection with carotenoids in glaucoma. Oftalmologia. 2003;59(4):70-75.
Neufeld AH. New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. Journal of glaucoma. 1998;7(6):434-438.
Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma? Archives of ophthalmology. 1999;117(11):1540-1544.
Abizgyldina GSh. Experience of glaucomatous optic neuropathy combined treatment. Meditsinskiy vestnik Bashkortostana. 2014;9(2):15-18. (In Russ.)
Alekseev VN, Sadkov VI, Aksenova AL, Shasha D. Neiroprotektsiya pri POUG. V sbornike: pod red. Nesterov A.P. i dr. Glaukoma: teorii, tendentsii, tekhnologii: materialy VI Mezhdunarodnoi konferentsii, Moskva, 5 dekabrya 2008;31-45. (In Russ.)
Astakhov YuS, Butin EV, Morozova NV, Sokolov VO. Results of Retinalamin use in patients with primary open-angle glaucoma. Glaukoma. 2006;2:43-47. (In Russ.)
Egorov EA, Egorova TE, Shramko YuG. Efficacy of Retinalamin use in patients with compensated primary open-angle glaucoma. RMJ Klinicheskaya Oftalmologiya. 2014;15(4):188-193. (In Russ.)
Ilyina SN, Lomanik IF, Logosh SM, Shavlovskaya TV. Retinalamin in neuroprotective therapy of primary open-angle glaucoma patients. Ofthalmologiya Vostochnaya Evropa. 2012;15(4):96-101. (In Russ.)
Mazunin IYu. Results of 'Retinalamin' neuroprotector use after laser trabeculoplasty in compensated primary open-angle glaucoma treatment. Meditsinskiy almanakh. 2014;31(1):69-73. (In Russ.)
Malyshevskaya TN, Dolgova IG. Comparative effectiveness analysis of different methods of neuroprotective therapy in patients with non-progressive advanced primary glaucoma. Natsional’nyi zhurnal glaukoma. 2016;15(2):84-92. (In Russ.)
Rozhko YuI, Marchenko LN, Rebenok NA, Krivun AO. et al. Neuroprotective action of Cortexin and Retinalamin in primary open-angle glaucoma treatment. Problemy zdorovia i ekologii. 2010;25(3):50-55. (In Russ.)